Risk of Hepatocellular Carcinoma in Patients Treated With ETV vs TDF for Chronic Hepatitis B With Compensated Cirrhosis
Conditions: Hepatitis B, Chronic; Hepatocellular Carcinoma; Compensated Cirrhosis Interventions: Drug: Entecavir; Drug: Tenofovir Disoproxil Sponsors: Qing XIe; Shanghai MedSci Healthcare Co. Ltd Enrolling by invitation
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer & Oncology | Carcinoma | Cirrhosis | Hepatitis | Hepatitis B | Hepatocellular Carcinoma | Liver Cancer | Research